Comment_老虎社区_美港股上老虎

Ladious
2021-10-28

Comment

Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise

Oppenheimer has downgraded Aurinia Pharmaceuticals(NASDAQ:AUPH)from outperform to perform following

Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":854149786,"tweetId":"854149786","gmtCreate":1635429790469,"gmtModify":1635429853824,"author":{"id":3568089111846836,"idStr":"3568089111846836","authorId":3568089111846836,"authorIdStr":"3568089111846836","name":"Ladious","avatar":"https://static.tigerbbs.com/8c7a0777ad403c9882135b0067a24d7e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Comment</p></body></html>","htmlText":"<html><head></head><body><p>Comment</p></body></html>","text":"Comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/854149786","repostId":1134279363,"repostType":4,"repost":{"id":"1134279363","kind":"news","pubTimestamp":1635428869,"share":"https://www.laohu8.com/m/news/1134279363?lang=&edition=full","pubTime":"2021-10-28 21:47","market":"us","language":"en","title":"Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise","url":"https://stock-news.laohu8.com/highlight/detail?id=1134279363","media":"seekingalpha","summary":"Oppenheimer has downgraded Aurinia Pharmaceuticals(NASDAQ:AUPH)from outperform to perform following ","content":"<p>Oppenheimer has downgraded Aurinia Pharmaceuticals(NASDAQ:AUPH)from outperform to perform following a report thatthe company may be acquired by Bristol-Myers Squibb(NYSE:BMY).</p>\n<p>In addition, the firm says that the current share price reflects appropriate valuation.</p>\n<p>Oppenheimer has a $32 price target (~7% upside)</p>\n<p>\"We view the cart being placed somewhat at front of the horse at these levels,\" analyst Justin Kim writes.</p>\n<p>He adds that he continues to see blockbuster potential for the lupus drug Lupkynis (voclosporin).</p>\n<p>Kim says the recent share upside could subside if the M&amp;A speculation ends up not happening.</p>\n<p>Earlier this week, Citi said thata Bristol acquisition of Aurinia makes sense.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3760060-oppenheimer-cuts-aurinia-to-perform-on-ma-chatter-recent-share-price-rise><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oppenheimer has downgraded Aurinia Pharmaceuticals(NASDAQ:AUPH)from outperform to perform following a report thatthe company may be acquired by Bristol-Myers Squibb(NYSE:BMY).\nIn addition, the firm ...</p>\n\n<a href=\"https://seekingalpha.com/news/3760060-oppenheimer-cuts-aurinia-to-perform-on-ma-chatter-recent-share-price-rise\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3760060-oppenheimer-cuts-aurinia-to-perform-on-ma-chatter-recent-share-price-rise","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1134279363","content_text":"Oppenheimer has downgraded Aurinia Pharmaceuticals(NASDAQ:AUPH)from outperform to perform following a report thatthe company may be acquired by Bristol-Myers Squibb(NYSE:BMY).\nIn addition, the firm says that the current share price reflects appropriate valuation.\nOppenheimer has a $32 price target (~7% upside)\n\"We view the cart being placed somewhat at front of the horse at these levels,\" analyst Justin Kim writes.\nHe adds that he continues to see blockbuster potential for the lupus drug Lupkynis (voclosporin).\nKim says the recent share upside could subside if the M&A speculation ends up not happening.\nEarlier this week, Citi said thata Bristol acquisition of Aurinia makes sense.","news_type":1},"isVote":1,"tweetType":1,"viewCount":818,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}